A liver protein called FGL1 appears to be a major driver of atherosclerosis, the disease that clogs arteries. According to Gram Research analysis, patients with atherosclerosis had significantly higher FGL1 levels in their blood, and the amount of FGL1 correlated with how severely their arteries were blocked. In mice, blocking FGL1 reduced plaque buildup substantially, suggesting this protein could become a new treatment target for heart disease.
Scientists discovered that a protein called FGL1, made by your liver, may play a major role in causing heart disease and clogged arteries. When people eat high-fat diets, their livers produce more FGL1, which travels through the bloodstream and damages blood vessel walls. According to Gram Research analysis, this protein appears to be a key player in atherosclerosis, the disease that hardens and narrows arteries. The good news: researchers found that blocking this protein in mice significantly reduced plaque buildup in arteries. This discovery opens new possibilities for treating heart disease by targeting this specific liver protein instead of just managing symptoms.
Key Statistics
A 2026 research study found that atherosclerosis patients had significantly elevated plasma FGL1 levels compared to healthy individuals, with FGL1 levels correlating directly with the severity of arterial stenosis.
In laboratory mice, hepatic FGL1 overexpression accelerated atherosclerosis development, while liver-specific FGL1 knockdown reduced plaque burden, demonstrating a direct causal relationship between this liver protein and arterial disease.
Therapeutic interventions targeting the FGL1-integrin beta-1 axis using blocking antibodies, neutralizing antibodies, or RGD peptides effectively attenuated endothelial injury and atherogenic progression in murine atherosclerosis models.
High-fat diet exposure specifically upregulated hepatic FGL1 expression in mice, establishing a direct link between dietary fat intake and increased production of this atherosclerosis-driving liver protein.
The Quick Take
- What they studied: Whether a liver protein called FGL1 causes atherosclerosis, the disease where fatty plaques build up inside arteries and restrict blood flow.
- Who participated: The study included both human patients with atherosclerosis and laboratory mice. Researchers compared FGL1 levels in people with clogged arteries to healthy people, and tested what happens when mice produce more or less of this protein.
- Key finding: Patients with atherosclerosis had significantly higher FGL1 levels in their blood, and the amount of FGL1 correlated directly with how severe their arterial blockages were. When researchers gave mice extra FGL1, their atherosclerosis got worse. When they reduced FGL1 in mouse livers, plaque buildup decreased substantially.
- What it means for you: This research suggests that managing liver health and reducing high-fat diet intake may help lower FGL1 production and protect your arteries. However, this is early-stage research, and new treatments targeting FGL1 are not yet available for patients. Talk to your doctor about heart disease prevention strategies based on current evidence.
The Research Details
Researchers used a combination of clinical studies and laboratory experiments. First, they measured FGL1 levels in blood samples from atherosclerosis patients and compared them to healthy controls. They also examined how severe each patient’s arterial blockages were to see if FGL1 levels matched disease severity. In parallel, they conducted detailed laboratory studies using mice to understand exactly how FGL1 causes damage. They created mice that produced extra FGL1 and mice with reduced FGL1 to test cause and effect. They also tested what happens when they inject FGL1 directly into mice and when they use blocking antibodies or other molecules to stop FGL1 from working.
This multi-layered approach combining human data with controlled animal experiments is important because it shows the protein is relevant to real patients while also revealing the exact biological mechanisms at work. The researchers could control variables in mice that cannot be controlled in humans, allowing them to prove that FGL1 directly causes the damage rather than just being associated with it. This type of evidence is necessary before developing new treatments.
The study demonstrates strong evidence by showing consistent results across multiple approaches: elevated FGL1 in patient blood samples, correlation with disease severity, and reproducible effects in animal models. The use of both gain-of-function experiments (adding more FGL1) and loss-of-function experiments (removing FGL1) strengthens the causal evidence. The identification of the specific molecular pathway by which FGL1 damages blood vessels adds mechanistic credibility. However, animal studies do not always translate to human treatments, and the human portion appears to be observational rather than a randomized controlled trial.
What the Results Show
Patients with atherosclerosis had significantly elevated FGL1 levels in their blood compared to healthy individuals. The amount of FGL1 in the blood correlated directly with how severely their arteries were blocked, suggesting FGL1 levels could potentially predict disease severity. In mice, overproducing FGL1 in the liver accelerated atherosclerosis development, while reducing liver FGL1 production slowed plaque formation. When researchers injected FGL1 directly into mice, it caused rapid endothelial injury, meaning damage to the inner lining of blood vessels where plaques form. The damage occurred through a specific biological pathway: FGL1 binds to a protein called integrin beta-1 on blood vessel cells, triggering a cascade of molecular signals that reprograms the cells and makes them vulnerable to plaque formation.
Researchers found that high-fat diets specifically increased FGL1 production in the liver, suggesting a direct link between diet and this disease mechanism. The blocking antibodies and peptides that interrupted the FGL1-integrin pathway effectively reduced endothelial injury and slowed atherosclerosis in mice, demonstrating that this pathway is a viable therapeutic target. The study identified the exact molecular binding site where FGL1 attaches to integrin beta-1, providing a precise target for future drug development.
FGL1 was previously known to affect cancer development and metabolic dysfunction, but its role in heart disease was unknown. This research establishes FGL1 as a new player in atherosclerosis, filling a gap in understanding how the liver influences vascular health. The discovery that a hepatokine, a protein made by the liver, directly drives atherosclerosis adds to growing evidence that liver health is intimately connected to cardiovascular health beyond just cholesterol metabolism.
The study did not specify the exact number of human patients studied, making it difficult to assess statistical power. The human portion appears to be observational, showing correlation rather than proving causation in people. Results come from laboratory mice, which do not always translate directly to humans. The study did not test whether existing atherosclerosis treatments affect FGL1 levels. Long-term safety and efficacy of FGL1-blocking treatments have not been tested in humans. The research does not address whether FGL1 is the only mechanism driving atherosclerosis or just one contributing factor.
The Bottom Line
Based on current evidence, maintain a heart-healthy diet low in saturated fats and high in whole foods, as this appears to reduce FGL1 production. Continue following established cardiovascular prevention guidelines including regular exercise, not smoking, and managing blood pressure and cholesterol. Do not expect FGL1-targeting treatments to be available soon, as they are still in early research stages. If you have atherosclerosis or family history of heart disease, work with your doctor on proven prevention and treatment strategies. Confidence level: Moderate for dietary recommendations, Low for FGL1-specific interventions.
People with atherosclerosis, those with family history of heart disease, people with metabolic syndrome or obesity, and anyone eating a high-fat diet should find this research relevant. People with normal arteries and healthy lifestyles may benefit from knowing that liver health influences heart health. Researchers and pharmaceutical companies should care about this as a potential new drug target. People should not self-diagnose or self-treat based on FGL1 levels, as clinical tests are not yet available.
If dietary changes reduce FGL1 production, cardiovascular benefits typically take months to years to become apparent. New treatments targeting FGL1 are likely 5 to 10 years away from human testing, and potentially 10 to 15 years from widespread availability. Existing atherosclerosis treatments remain the standard of care for now.
Frequently Asked Questions
What is FGL1 and why does it matter for heart disease?
FGL1 is a protein made by your liver that appears to damage blood vessel walls and trigger atherosclerosis. Research shows patients with clogged arteries have much higher FGL1 levels, suggesting this protein is a key driver of heart disease that could become a new treatment target.
Does eating a high-fat diet increase FGL1 production?
Yes, according to this research, prolonged high-fat diet exposure specifically increases FGL1 production in the liver. Reducing dietary fat intake may help lower FGL1 levels and protect your arteries from damage.
Can doctors test my FGL1 levels to predict heart disease?
Not yet. While this research shows FGL1 levels correlate with atherosclerosis severity in patients, clinical FGL1 testing is not currently available. Doctors still use established tests like cholesterol levels and imaging to assess heart disease risk.
When will treatments targeting FGL1 be available?
FGL1-targeting treatments are still in early research stages. Blocking antibodies and other interventions worked in mice, but human clinical trials have not yet begun. New treatments typically take 10 to 15 years from discovery to availability.
Should I change my diet based on this FGL1 research?
This research supports existing heart-healthy diet recommendations: reduce saturated fat and eat more whole foods. These changes may lower FGL1 production and reduce atherosclerosis risk, though proven cardiovascular benefits take months to years to appear.
Want to Apply This Research?
- Track daily dietary fat intake in grams, aiming to stay below recommended limits. Monitor weekly average, as this correlates with liver FGL1 production. Log any cardiovascular symptoms or test results from your doctor.
- Reduce high-fat foods and increase whole grains, vegetables, and lean proteins. Set a specific goal like reducing saturated fat to under 10 percent of daily calories. Use the app to log meals and see patterns in how diet choices affect your cardiovascular health markers over time.
- Track weight, blood pressure, and cholesterol levels monthly if available. Log exercise frequency and duration weekly. Note any changes in energy, shortness of breath, or chest discomfort. Share trends with your healthcare provider to assess overall cardiovascular health progression.
This article summarizes research findings and is not medical advice. FGL1 testing and FGL1-targeting treatments are not currently available for patients. If you have atherosclerosis, family history of heart disease, or cardiovascular symptoms, consult your healthcare provider about proven prevention and treatment strategies. Do not make changes to your diet or medications based solely on this research without discussing with your doctor. This research is preliminary and results from animal studies do not always translate to human treatments.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.